New Structure of Business Operations for a Global Pharmaceutical Company

TakedaAs part of its "Transformation into a New Takeda", Takeda Pharmaceutical Company Limited ("Takeda") has implemented several strategies to realize its corporate vision of achieving "sustainable growth" by 2015 through "innovation" and "culture". The latest development came with the recent closing of the Nycomed acquisition, whereby Takeda took another significant step towards globalization. Today, Takeda announces the establishment of the positions of Chief Medical & Scientific Officer (CMSO) and Chief Commercial Officer (CCO), to strengthen the company's governance and business operations as it moves forward to fully integrate the Nycomed organization and become a truly global pharmaceutical company.

In order to further strengthen its global research and development activities, Takeda has abolished the position of Chief Scientific Officer and established the new position of CMSO. Takeda board member Dr. Tadataka Yamada, a medical doctor and scientist with vast global experience in pharmaceutical R&D, has been appointed CMSO to boost research and development productivity by driving innovation and skillfully allocating resources.

In addition, the positions of International Operations (Americas/Europe) and International Operations (North Asia) have been abolished to be replaced by the CCO, who will preside over Takeda's global sales structure (with the exclusion of Millennium and Japanese domestic sales), including most former Nycomed countries and functions. Takeda has appointed board member Dr. Frank Morich as CCO, who has extensive experience at top management in the global pharmaceutical industry. Dr. Morich will drive sales strategies in the important US and EU markets, and also in the fast-growing emerging markets.

Takeda is continually challenging itself to create innovative medicines that transform treatment paradigms to prevent and cure disease, focusing particularly on fields with unmet medical needs, and will continue to globalize its business to deliver its products to patients and health care providers worldwide.

Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...